Supernus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
SUPN Supernus Pharmaceuticals Inc
AMWL American Well Corp
DGLD.NV Credit Suisse AG
HMPQ HempAmericana Inc
$SPMCKCP S&P GSCI Coffee Multiple Contract (U
WYNN Wynn Resorts Ltd
BAC Bank of America Corp
KNDI Kandi Technologies Group Inc
$RFTREES Refinitiv Eurozone ESG Select Index
TCEHY Tencent Holdings Ltd
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Postmarket

Last Trade
Delayed
$29.20
-0.02 (-0.07%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$29.22
Day's Change
0.43 (1.49%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
29.80
Day's Low
28.49
Volume
(Above Average)
Volume:
690,133

10-day average volume:
582,146
690,133

Latest Earnings (Q3 ending 09/2020)

Q3
$0.74
Q3 Consensus estimate
$0.30

Latest Earnings Estimate Range

Highest
estimate
$0.37
Mean
estimate
$0.30
Lowest
estimate
$0.20

Quarterly Consensus Estimates and Ranges

SUPN's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.